FR2160293A1 - Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity - Google Patents

Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity

Info

Publication number
FR2160293A1
FR2160293A1 FR7141308A FR7141308A FR2160293A1 FR 2160293 A1 FR2160293 A1 FR 2160293A1 FR 7141308 A FR7141308 A FR 7141308A FR 7141308 A FR7141308 A FR 7141308A FR 2160293 A1 FR2160293 A1 FR 2160293A1
Authority
FR
France
Prior art keywords
sila
dioxa
hexanol
dimethyl
compsn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7141308A
Other languages
French (fr)
Other versions
FR2160293B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUEYNE JEAN FR
Original Assignee
GUEYNE JEAN FR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUEYNE JEAN FR filed Critical GUEYNE JEAN FR
Priority to FR7141308A priority Critical patent/FR2160293A1/en
Publication of FR2160293A1 publication Critical patent/FR2160293A1/en
Application granted granted Critical
Publication of FR2160293B1 publication Critical patent/FR2160293B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/60—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which all the silicon atoms are connected by linkages other than oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Therapeutic compsn. contg. as active component poly (1.1'-dimethyl-1-sila-2,6-dioxa-4-hexanol). 1g/kg s.c. in rats caused no toxic effects. The active cpd. reduces the rate of calcium osteolysis in rabbits and has a protective action against X-rays and ionizing radiation. It increases the rate of penetration of the skin by salicylic acid in guinea-pigs. Dosage unis contain 25-50 mg in 5 or 10 ml or soln. for i.u. injection every other day or i.m. injection daily.
FR7141308A 1971-11-18 1971-11-18 Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity Granted FR2160293A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7141308A FR2160293A1 (en) 1971-11-18 1971-11-18 Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7141308A FR2160293A1 (en) 1971-11-18 1971-11-18 Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity

Publications (2)

Publication Number Publication Date
FR2160293A1 true FR2160293A1 (en) 1973-06-29
FR2160293B1 FR2160293B1 (en) 1975-02-07

Family

ID=9085979

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7141308A Granted FR2160293A1 (en) 1971-11-18 1971-11-18 Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity

Country Status (1)

Country Link
FR (1) FR2160293A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510407A1 (en) * 1981-07-28 1983-02-04 Duffaut Charles Organo-silanol and adenosine phosphoric acid deriv. compsn. - for cellulitis treatment by ionokinesis, opt. contain organic acids
FR2559063A1 (en) * 1984-02-08 1985-08-09 Leribault Loic THERAPEUTIC USE COMPOSITIONS COMPRISING ORGANO-SILICY COMPOUNDS
FR2591890A1 (en) * 1985-12-23 1987-06-26 Leribault Loic THERAPEUTIC USE COMPOSITION COMPRISING ORGANO-SILICY COMPOUNDS
RU2814974C1 (en) * 2023-06-19 2024-03-07 Федеральное бюджетное учреждение "Федеральное управление по безопасному хранению и уничтожению химического оружия при Министерстве промышленности и торговли Российской Федерации (войсковая часть 70855)" Method of producing trimethylalkoxysilanes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510407A1 (en) * 1981-07-28 1983-02-04 Duffaut Charles Organo-silanol and adenosine phosphoric acid deriv. compsn. - for cellulitis treatment by ionokinesis, opt. contain organic acids
FR2559063A1 (en) * 1984-02-08 1985-08-09 Leribault Loic THERAPEUTIC USE COMPOSITIONS COMPRISING ORGANO-SILICY COMPOUNDS
EP0152366A2 (en) * 1984-02-08 1985-08-21 Loic Le Ribault Compositions for therapeutic use comprising organo-silicon compounds
EP0152366A3 (en) * 1984-02-08 1988-01-27 Leribault Loic Compositions for therapeutic use comprising organo-silicon compounds
FR2591890A1 (en) * 1985-12-23 1987-06-26 Leribault Loic THERAPEUTIC USE COMPOSITION COMPRISING ORGANO-SILICY COMPOUNDS
EP0228978A1 (en) * 1985-12-23 1987-07-15 Loic Le Ribault Compositions for therapeutical use containing organo-silico-compounds
US5391546A (en) * 1985-12-23 1995-02-21 Michel B. Lamothe Composition comprising organo-silicon compounds for therapeutic use
RU2814974C1 (en) * 2023-06-19 2024-03-07 Федеральное бюджетное учреждение "Федеральное управление по безопасному хранению и уничтожению химического оружия при Министерстве промышленности и торговли Российской Федерации (войсковая часть 70855)" Method of producing trimethylalkoxysilanes

Also Published As

Publication number Publication date
FR2160293B1 (en) 1975-02-07

Similar Documents

Publication Publication Date Title
MY101207A (en) Treatment of diseases caused by retroviruses
DE69226369D1 (en) System with increased skin penetration for improved topical administration of drugs
EP0316065A3 (en) Improved transdermal drug delivery device
HU9401107D0 (en) Enhanced skin penetration system for improved topical delivery of drugs
MY102378A (en) Transdermal delivery system.
KR920002144A (en) Inflammatory bowel disease prevention and treatment containing zinc L-carnosine salt or its complex as an active ingredient
ES2077530A1 (en) Pharmaceutical products for curing tumorous diseases and process for preparing same
KR910019618A (en) Pharmaceutical composition for treating erectile dysfunction
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
CA2046014A1 (en) Reduction or prevention of skin irritation by drugs
EP0620004A4 (en) Medicinal composition.
FR2160293A1 (en) Aqueous poly(1,1'-dimethyl-1-sila-2,6-dioxa-4-hexanol) compsn - with antiinflammatory and reticuloendothelial activity
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
JPS6483020A (en) Medicinal composition for preventing or treating aids
Fabre et al. Nabilone, a cannabinoid, in the treatment of anxiety: An open-label and double-blind study.
ES2042831T3 (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS.
FR2457691A1 (en) Magnesium glycero:phosphate, phosphorus tri:iodide and uranyl nitrate - used as homeopathic medicament association for treatment of chronic infections when used at dilutions of 1 in 100 million
SG46482A1 (en) Soluble calcium lactate/quindonecarboxylic acids on naphthy-drinecarboxylic acids complexes as nonirritating parenteral forms
GB2208798B (en) Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
DE69109933D1 (en) Use of mizoribin to treat or prevent multiple sclerosis.
Feuerstein et al. Single drug therapy with sodium valproate in primary generalized epilepsy. Phase 2: Long term efficacy and tolerance study.
Conti et al. Befuraline: A multicenter controlled study on major depression.
FR2424028A1 (en) Salts of hetero-polyanion contg. tungsten and arsenic - useful in human and veterinary medicine as antivirals, e.g. against leukaemia
ES458413A1 (en) Pharmaceutical composition